KF
CASC

Krilogy Financial’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Krilogy Financial’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-200
Closed -$1K – 841
2017
Q4 		$1K Hold
200
– – ﹤0.01% 758
2017
Q3 		$1K Hold
200
– – ﹤0.01% 797
2017
Q2 		$1K Buy
200
+167
+506% +$663 ﹤0.01% 713
2017
Q1 		$0 Hold
33
– – ﹤0.01% 734
2016
Q4 		$0 Hold
33
– – ﹤0.01% 786
2016
Q3 		$0 Hold
33
– – ﹤0.01% 799
2016
Q2 		$0 Hold
33
– – ﹤0.01% 779
2016
Q1 		$1K Buy
+33
New +$254 ﹤0.01% 677
2015
Q4 		– Sell
-233
Closed -$4K – 632
2015
Q3 		$4K Buy
+233
New +$4.78K ﹤0.01% 503

Krilogy Financial's CASC Position: Q1 2018 in Review

Krilogy Financial sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 200 shares — an estimated $1K sold.

Krilogy Financial first reported a position in CASC in Q3 2015 and held it in 9 quarters. The position peaked at $4K in Q3 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Krilogy Financial reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Krilogy Financial sold 200 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1K.
  • Krilogy Financial first reported a position in Cascadian Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
  • Krilogy Financial's Cascadian Therapeutics, Inc. position peaked at $4K in Q3 2015.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Krilogy Financial's 13F filing for Q1 2018, filed 15 May 2018.